Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | BRD1 | O95696 | 1/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435058 | 1.00 | BRD4 (0.60) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL377843 | 0.92 | BRD4 (0.60) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL377653 | 0.84 | BRD4 (0.60) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL616993 | 0.82 | BRD4 (0.53) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL349316 | 0.82 | BRD4 (0.62) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30434479 | 0.80 | BRD4 (0.65) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL120808 | 0.80 | BRD4 (0.65) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL348894 | 0.80 | BRD4 (0.77) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL121947 | 0.79 | BRD4 (0.77) | BRD4HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30434343 | 0.79 | BRD4 (0.77) | BRD4HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | claimed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | claimed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | claimed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| CN-102458405-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-05-16 | — | — | CN | claimed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885HDAC1 30/4885HDAC3 54/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.